The NC1 domain of type XIX collagen inhibits in vivo melanoma growth

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 506-514

  Ramont, Laurent ^a   Brassart Pasco, Sylvie ^a   Thevenard, Jessica ^a   Deshorgue, Aurélie ^a   Venteo, Lydie ^a   Laronze, Jean Yves ^a   Pluot, Michel ^a   Monboisse, Jean Claude ^a   Maquart, François Xavier ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN TYPE 19 NC1 DOMAIN; MATRIGEL; MATRIX METALLOPROTEINASE 14; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BASEMENT MEMBRANE; BLOTTING, WESTERN; CELL ADHESION; CELL PROLIFERATION; COLLAGEN; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 14; MELANOMA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847345590     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0207     Document Type: Article

References (39)

1. Yoshioka H, Zang H, Ramirez F, et al. Synteny between the loci from a novel FACIT-like collagen locus (D6S228E) and α1 (XIX) collagen (COL19A1) on 6912-14 in human. Genomics 1992; 13:884-6.
2. Myers JC, Sun MJ, D'Ippolito JA, Jabs EJ, Neilson EG, Dion AS. Human cDNA clones transcribed from an unusually high-molecular weight encode a new collagen chain. Gene 1993;123:211-7.
3. Inoguchi K, Yoshioka H, Khaleduzzaman M, Ninomiya Y. The mRNA for α 1(XIX) collagen chain, a new member of FACITs, contains a long unusual 3′ untranslated region and displays many unique splicing variants. J Biochem 1995; 117:137-46.
4. Myers JC, Li D, Bageris A, Abraham V, Dion AS, Amenta PS. Biochemical and immunohistochemical characterization of human type XIX defines a novel class of basement membrane zone collagens. Am J Pathol 1997;151:1729-40.
5. Sumiyoshi H, Inoguchi K, Khaleduzzaman M, Ninomiya Y, Yoshioka H. Ubiquitous expression of the α1(XIX) collagen gene (Col19a1) during mouse embryogenesis becomes restricted to a few tissues in the adult organism. J Biol Chem 1997;272:17104-11.
6. Sumiyoshi H, Laub F, Yoshioka H, Ramirez F. Embryonic expression of type XIX collagen is transient and confined to muscle cells. Dev Dyn 2001; 220:155-62.
7. Sumiyoshi H, Mor N, Lee SY, et al. Esophageal muscle physiology and morphogenesis require assembly of a collagen XIX-rich basement membrane zone. J Cell Biol 2004; 166:591-600.
8. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967-79.
9. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003;22:3172-9.
10. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-36.
11. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
12. Davis GE, Bayless KJ, Davis MJ, Meininger GA. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol 2000; 156:1489-98.
13. Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. An introduction to matrikines: Extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol 2004;49:199-202.
14. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
15. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
16. 3 correlates with activation of membrane-type matrix metalloproteinase 1 (MT1-MMP) and matrix metalloproteinase 2 in human melanoma cells in vitro and in vivo. Int J Cancer 2000;87:12-9.
17. Kurschat P, Zigrino P, Nischt R, et al. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 1999;274:21056-62.
18. Lida J, Wilhelmson KL, Price MA, et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 2004;122:167-76.
19. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003; 194:1-11.
20. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 2004;23:317-29.
21. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003;94:569-74.
22. Koike T, Vernon RB, Hamner MA, Sadoun E, Reed MJ. MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels. J Cell Biochem 2002;86: 748-58.
23. Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003;22: 55-61.
24. Bouifraden S, Drouot C, el Hadrami M, et al. Some of the amino acid chemistry going on in the laboratory of amino acids, peptides and proteins. Amino Acids 1999; 16:345-79.
25. Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M, Pouckova P. Mixture of trypsin, chymotrypsin, and papain reduces formation of metastases and extends survival time of C57B16 mice with syngenic melanoma B16. Cancer Chemother Pharmacol 2001;47:16-22.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
27. Abramoff MD, Magelhaes PJ. Image processing with Image J. Biophotonics International 2004; 11:36-42.
28. Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX, Monboisse JC. In vivo overexpression of turnstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 2004;301: 251-65.
29. Pasco S, Han J, Gillery P, et al. A specific sequence of the noncollagenous domain of the α3(IV) chain of type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res 2000;60:467-73.
30. Kuo CJ, LaMontagne KR, Garcia-Cardena G, et al. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol 2001;152:1233-46.
31. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003;278: 37632-6.
32. Chavakis E, Dimmerler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 2002;22: 887-93.
33. Hofmann UB, Westpha JR, Zendman A, Becker JC, Ruiter DJ, Van Muijen GNP. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 19:1245-56.
34. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002; 115:3427-38.
35. Robinet A, Fahem A, Cauchard JH, et al. Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci 2005;118: 343-56.
36. Sounni NE, Roghi C, Chabottaux V, et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004; 279:13564-74.
37. Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002; 16:555-64.
38. Deryugina EI, Soroceanu L, Strongin AY. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 2002;62:580-8.
39. Hajitou A, Grignet-Debrus C, Davy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-4.